In 1881, Curtius synthesized the first
N-protected dipeptides containing blocked amino groups like acyl, acetyl, or benzoyl (
1). Although, at that time, there was no particular way to deprotect the nitrogen atom without breaking the peptide bond. In 1901, Fischer and Fourneau developed the Gly-Gly dipeptide (
2). This is why Emil Fischer is called the "founding father" of peptide chemistry. His significant impact on peptide development was using α-chloro acid chloride to condense with an amino ester and then replacing the Cl group with an amine to obtain a peptide. Nonetheless, this synthesis gives racemate peptides (
3). Through this method, dipeptides, and later tripeptides and polypeptides, were prepared.
It was in the midst of the progress of this discovery that World War I began, and its progress was postponed for fifty years. However, Bergmann and Zervas found that the Cbz-protecting group kept the configuration of the chiral center and prevented racemization during carbamate formation, which is a good replacement for
N-acyl- or
N-benzoyl-protected amino acids (
4). This was a revolutionary discovery in the synthesis of peptides. After World War II, du Vigneaud isolated and identified the amino acid sequence of the polypeptide hormone 'oxytocin' and then synthesized it (
5-
7). Because of his discovery, du Vigneaud was awarded a Noble Prize in 1955.
It is necessary to protect the amine groups and deprotect them in a timely manner to prevent the production of by-products and self-condensation of amino acids. As mentioned above, Cbz-protected amines can be deprotected through hydrogenolysis using Pd-charcoal or HBr (
8). The need for a cheaper protection-deprotection method led to the discovery of the
tert-butyloxycarbonyl (Boc) group in 1957 (
9). The conventional methods for deprotection of N-Boc amines are: (1) heating the solution in the presence of HCl (
10); and (2) dissolving the protected amine in a mixture of HCl/TFA at room temperature (
11). Once the problem of protecting amines was resolved, the efficient formation of peptide bonds was another challenge. Meanwhile, Sheehan and Hess introduced a new method for the efficient formation of peptide bonds using ‘dicyclohexyl carbodiimide’ (DCC) as a coupling reagent (
12). In 1972, Carpino and Han found a new way of amine protection using the 9-fluorenylmethoxycarbonyl protecting group (Fmoc). However, deprotecting nitrogen atoms containing the Fmoc group is rapidly performed in the presence of secondary amines, especially piperidine, in DMF (
13). This development is summarized in
Figure 1.
A schematic history of peptide developments
Despite all these advances, until the early 1960s, the synthesis of peptides was so difficult that a project took one to two years until Merrifield's innovation resulted in a great revolution in peptide synthesis (
14). In the solid phase peptide synthesis (SPPS) method, an
N-protected amino acid is bound to a resin or other substrates from its C-terminus via an amide or an ester bond. After amine deprotection, it is reacted with the carbonyl group of the subsequent
N-protected amino acid. This cycle is repeatable to achieve the favorite peptide chain. Finally, the formed peptide is cleaved from the resin (
15,
16). Soon after, various types of beads were introduced and commercialized, like polystyrenes, BHA, and Wang resins (
17).
Therefore, modified and improved synthetic peptides have emerged on the market. When Novartis Pharmaceuticals introduced lypressin, an antidiuretic hormone and analogue of vasopressin to regulate the tonicity of body fluids, in the 1970s, the therapeutic peptide business was born. Most physiological processes are regulated by peptides, and they may act as endocrine and paracrine signals, neurotransmitters, or growth factors. Although peptides do not have all of the desirable characteristics of an ideal medicine, they have properties like high affinity, specificity, and the capability to stay on target longer due to their size. Moreover, as therapeutic candidates, peptides have a predominantly specific activity compared to small molecules because peptides are simply destroyed in the human body. According to these properties, peptides are becoming more popular than other medicines for certain diseases, disorders, and infections, where the direct introduction of therapeutic peptides is desirable. Furthermore, peptides generally have low adverse effects and have become appealing medication design choices (
18-
21).
In 2015 and 2020, the market for therapeutic peptides was valued at $17,568.0 and 28,510.60 million, respectively, which is expected to increase to $51,360.30 million in 2026 (
22). Now, eighty FDA-approved therapeutic peptides are on the market, and hundreds of peptides are in clinical and preclinical trials (
23). As a result, peptide and protein-based pharmaceuticals are rapidly becoming an important class of medications. They are likely to replace many existing small-molecule pharmaceuticals in the very near future.